RU2019119368A -
The use of 1 - [(3,5-dimethyladamantan-1-yl) amino] -3- (6-fluoro-3,4-dihydro-1H-carbazol-9 (2H) -yl) propan-2-ol hydrochloride as agents for the prevention and treatment of cognitive disorders and neurodegenerative diseases, the pathogenesis of which is associated with AMPA -type of glutamate receptors and a drug based on it
- Google Patents
The use of 1 - [(3,5-dimethyladamantan-1-yl) amino] -3- (6-fluoro-3,4-dihydro-1H-carbazol-9 (2H) -yl) propan-2-ol hydrochloride as agents for the prevention and treatment of cognitive disorders and neurodegenerative diseases, the pathogenesis of which is associated with AMPA -type of glutamate receptors and a drug based on it
Download PDF
Info
Publication number
RU2019119368A
RU2019119368ARU2019119368ARU2019119368ARU2019119368ARU 2019119368 ARU2019119368 ARU 2019119368ARU 2019119368 ARU2019119368 ARU 2019119368ARU 2019119368 ARU2019119368 ARU 2019119368ARU 2019119368 ARU2019119368 ARU 2019119368A
Федеральное Государственное Бюджетное Учреждение Науки Институт Физиологически Активных Веществ Российской Академии Наук (Ифав Ран)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федеральное Государственное Бюджетное Учреждение Науки Институт Физиологически Активных Веществ Российской Академии Наук (Ифав Ран)filedCriticalФедеральное Государственное Бюджетное Учреждение Науки Институт Физиологически Активных Веществ Российской Академии Наук (Ифав Ран)
Priority to RU2019119368ApriorityCriticalpatent/RU2019119368A/en
Publication of RU2019119368ApublicationCriticalpatent/RU2019119368A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Claims (13)
1. Применение гидрохлорида 1-[(3,5-диметиладамантан-1-ил)амино]-3-(6-фтор-3,4-дигидро-1Н-карбазол-9(2Н)-ил)пропан-2-ола формулы (1)1. Application of 1 - [(3,5-dimethyladamantan-1-yl) amino] -3- (6-fluoro-3,4-dihydro-1H-carbazol-9 (2H) -yl) propan-2-ol hydrochloride formulas (1)
(1)(one)в качестве средства для профилактики и лечения когнитивных расстройств и нейродегенеративных заболеваний, патогенез которых связан с АМРА -типом глутаматных рецепторов.as a means for the prevention and treatment of cognitive disorders and neurodegenerative diseases, the pathogenesis of which is associated with AMPA -type of glutamate receptors.2. Лекарственное средство в форме таблеток, капсул или инъекций, помещенных в фармацевтически приемлемую упаковку, для профилактики и лечения когнитивных расстройств и нейродегенеративных заболеваний, патогенез которых связан с АМРА типом глутаматных рецепторов, включающее фармацевтически эффективное количество гидрохлорида 1-((3,5-диметиладамантан-1-ил)амино)-3-(6-фтор-3,4-дигидро-1Н-карбазол-9(2Н)-ил)пропан-2-ола формулы (1) и фармацевтически приемлемый носитель.2. A medicinal product in the form of tablets, capsules or injections placed in a pharmaceutically acceptable package for the prevention and treatment of cognitive disorders and neurodegenerative diseases, the pathogenesis of which is associated with the AMPA type of glutamate receptors, including a pharmaceutically effective amount of hydrochloride 1 - ((3,5- dimethyladamantan-1-yl) amino) -3- (6-fluoro-3,4-dihydro-1H-carbazol-9 (2H) -yl) propan-2-ol of formula (1); and a pharmaceutically acceptable carrier.3. Лекарственное средство по п. 2 в виде капсулы для перорального введения, отличающееся тем, что оно содержит следующий состав компонентов (мг):3. A medicinal product according to claim 2 in the form of a capsule for oral administration, characterized in that it contains the following composition of components (mg):гидрохлорид 1-[(3,5-диметиладамантан-1-ил)амино]-3-(6-фтор-3,4-дигидро-1H-карбазол-9(2H)-ил)пропан-2-ола - 0,8 - 1,2 мг;1 - [(3,5-dimethyladamantan-1-yl) amino] -3- (6-fluoro-3,4-dihydro-1H-carbazol-9 (2H) -yl) propan-2-ol hydrochloride - 0, 8 - 1.2 mg;стеарат кальция E470 (Ph. Eur., USP) - 1,0 - 1,5 мг;calcium stearate E470 (Ph. Eur., USP) 1.0-1.5 mg;микрокристаллическая целлюлоза (Ph.Eur., USP) - до массы содержимого 130 мг.microcrystalline cellulose (Ph.Eur., USP) - up to a content weight of 130 mg.4. Лекарственное средство по п. 3, отличающееся тем, что оно содержит следующий состав компонентов (мг):4. A medicinal product according to claim 3, characterized in that it contains the following composition of components (mg):гидрохлорид 1-[(3,5-диметиладамантан-1-ил)амино]-3-(6-фтор-3,4-дигидро-1H-карбазол-9(2H)-ил)пропан-2-ола - 1,0 мг;1 - [(3,5-dimethyladamantan-1-yl) amino] -3- (6-fluoro-3,4-dihydro-1H-carbazol-9 (2H) -yl) propan-2-ol hydrochloride - 1, 0 mg;стеарат кальция E470 (Ph. Eur., USP) - 1,3 мг;calcium stearate E470 (Ph. Eur., USP) 1.3 mg;микрокристаллическая целлюлоза (Ph.Eur., USP) - до массы содержимого 130 мг.microcrystalline cellulose (Ph.Eur., USP) - up to a content weight of 130 mg.
RU2019119368A2019-06-212019-06-21
The use of 1 - [(3,5-dimethyladamantan-1-yl) amino] -3- (6-fluoro-3,4-dihydro-1H-carbazol-9 (2H) -yl) propan-2-ol hydrochloride as agents for the prevention and treatment of cognitive disorders and neurodegenerative diseases, the pathogenesis of which is associated with AMPA -type of glutamate receptors and a drug based on it
RU2019119368A
(en)
The use of 1 - [(3,5-dimethyladamantan-1-yl) amino] -3- (6-fluoro-3,4-dihydro-1H-carbazol-9 (2H) -yl) propan-2-ol hydrochloride as agents for the prevention and treatment of cognitive disorders and neurodegenerative diseases, the pathogenesis of which is associated with AMPA -type of glutamate receptors and a drug based on it
The use of 1 - [(3,5-dimethyladamantan-1-yl) amino] -3- (6-fluoro-3,4-dihydro-1H-carbazol-9 (2H) -yl) propan-2-ol hydrochloride as agents for the prevention and treatment of cognitive disorders and neurodegenerative diseases, the pathogenesis of which is associated with AMPA -type of glutamate receptors and a drug based on it
The use of 1 - [(3,5-dimethyladamantan-1-yl) amino] -3- (6-fluoro-3,4-dihydro-1H-carbazol-9 (2H) -yl) propan-2-ol hydrochloride as agents for the prevention and treatment of cognitive disorders and neurodegenerative diseases, the pathogenesis of which is associated with AMPA -type of glutamate receptors and a drug based on it
The use of 1 - [(3,5-dimethyladamantan-1-yl) amino] -3- (6-fluoro-3,4-dihydro-1H-carbazol-9 (2H) -yl) propan-2-ol hydrochloride as agents for the prevention and treatment of cognitive disorders and neurodegenerative diseases, the pathogenesis of which is associated with AMPA -type of glutamate receptors and a drug based on it
Use of 5- [2- (5-fluoropyrid-3-yl) ethyl] -2,8-dimethyl-2,3,4,5-tetrahydro-1h-pyrido [4,3-b] indole dihydrochloride as an agent for for the prevention and treatment of cognitive disorders and neurodegenerative diseases, the pathogenesis of which is associated with the AMPA type of glutamate receptors, a pharmaceutical composition and a drug based on it